FHL3 and metastatic malignant neoplasm in the lymph nodes: There is no significant difference in FHL3 expression in different groups such as gender (P = 0.67), age (P = 0.72), tumor size (P = 0.50), tumor location (P = 0.66), depth of invasion (P = 0.94), and lymph node metastasis (P = 0.77).